COMT Met (158) modulates facial emotion recognition in bipolar I disorder mood episodes
Carregando...
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2012
Editora
ELSEVIER SCIENCE BV
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
SANTOS JR., Domingos Rodrigues dos
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF AFFECTIVE DISORDERS, v.136, n.3, p.370-376, 2012
Resumo
Background: One of the many cognitive deficits reported in bipolar disorder (BD) patients is facial emotion recognition (FER), which has recently been associated with dopaminergic catabolism. Catechol-O-methyltransferase (COMT) is one of the main enzymes involved in the metabolic degradation of dopamine (DA) in the prefrontal cortex (PFC). The COMT gene polymorphism rs4680 (Val(158)Met) Met allele is associated with decreased activity of this enzyme in healthy controls. The objective of this study was to evaluate the influence of Val(158)Met on FER during manic and depressive episodes in BD patients and in healthy controls. Materials and methods: 64 BD type I patients (39 in manic and 25 in depressive episodes) and 75 healthy controls were genotyped for COMT rs4680 and assessed for FER using the Ekman 60 Faces (EK60) and Emotion Hexagon (Hx) tests. Results: Bipolar manic patients carrying the Met allele recognized fewer surprised faces, while depressed patients with the Met allele recognized fewer ""angry"" and ""happy"" faces. Healthy homozygous subjects with the Met allele had higher FER scores on the Hx total score, as well as on ""disgust"" and ""angry"" faces than other genotypes. Conclusion: This is the first study suggesting that COMT rs4680 modulates FER differently during BD episodes and in healthy controls. This provides evidence that PFC DA is part of the neurobiological mechanisms of social cognition. Further studies on other COMT polymorphisms that include euthymic BD patients are warranted. ClinicalTrials.gov Identifier: NCT00969.
Palavras-chave
Facial emotions, Bipolar disorder, Mania, Depression
Referências
- Adolphs R, 2003, NEUROPSYCHOLOGIA, V41, P1281, DOI 10.1016/S0028-3932(03)00064-2
- ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0
- Bertolino A, 2006, BIOL PSYCHIAT, V60, P1250, DOI 10.1016/j.biopsych.2006.03.078
- Bilder RM, 2004, NEUROPSYCHOPHARMACOL, V29, P1943, DOI 10.1038/sj.npp.1300542
- Blasi G, 2005, J NEUROSCI, V25, P5038, DOI 10.1523/JNEUROSCI.0476-05.2005
- Bosia M, 2007, NEUROSCI LETT, V417, P271, DOI 10.1016/j.neulet.2007.02.076
- Burdick KE, 2010, ACTA PSYCHIAT SCAND, V122, P499, DOI 10.1111/j.1600-0447.2010.01590.x
- Campos RN, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-72
- Chen CH, 2006, BIOL PSYCHIAT, V59, P31, DOI 10.1016/j.biopsych.2005.06.008
- Rocca CCD, 2009, REV BRAS PSIQUIATR, V31, P171
- Dickstein DP, 2007, BIPOLAR DISORD, V9, P679, DOI 10.1111/j.1399-5618.2007.00418.x
- Drabant EM, 2006, ARCH GEN PSYCHIAT, V63, P1396, DOI 10.1001/archpsyc.63.12.1396
- Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598
- EKMAN P, 1971, J PERS SOC PSYCHOL, V17, P124, DOI 10.1037/h0030377
- Ekman Paul, 1976, PICTURES FACIAL AFFE
- First M. B., 1996, STRUCTURED CLIN INTE
- Foland LC, 2008, PSYCHIAT RES-NEUROIM, V162, P27, DOI 10.1016/j.pscychresns.2007.04.007
- Gonul AS, 2009, INT REV PSYCHIATR, V21, P323, DOI 10.1080/09540260902962131
- GOSSELIN P, 1995, CAN J EXP PSYCHOL, V49, P313, DOI 10.1037/1196-1961.49.3.313
- Granon S, 2000, J NEUROSCI, V20, P1208
- HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
- Hariri AR, 2002, NEUROPSYCHOPHARMACOL, V27, P1036, DOI 10.1016/S0893-133X(02)00373-1
- Harmer CJ, 2002, BIOL PSYCHIAT, V51, P298, DOI 10.1016/S0006-3223(01)01249-5
- Jabben N, 2010, J CLIN PSYCHIAT, V71, P764, DOI 10.4088/JCP.08m04837yel
- Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662
- Kienast T, 2008, NAT NEUROSCI, V11, P1381, DOI 10.1038/nn.2222
- Kohler CG, 2011, PSYCHIAT RES, V188, P303, DOI 10.1016/j.psychres.2011.04.019
- Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007
- LAITINEN J, 1994, BIOTECHNIQUES, V17, P316
- Laitinen J, 1994, BIOTECHNIQUES, V17, P318
- Laitinen J, 1994, BIOTECHNIQUES, V17, P320
- Lelli-Chiesa G, 2011, PSYCHOL MED, V41, P779, DOI 10.1017/S0033291710001431
- Lembke A, 2002, AM J PSYCHIAT, V159, P302, DOI 10.1176/appi.ajp.159.2.302
- Malhi GS, 2007, BIPOLAR DISORD, V9, P345, DOI 10.1111/j.1399-5618.2007.00485.x
- Mattay VS, 2003, P NATL ACAD SCI USA, V100, P6186, DOI 10.1073/pnas.0931309100
- Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438
- Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36
- Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0
- Pinkham AE, 2003, AM J PSYCHIAT, V160, P815, DOI 10.1176/appi.ajp.160.5.815
- Rich BA, 2008, DEV PSYCHOPATHOL, V20, P529, DOI 10.1017/S0954579408000266
- Schott BH, 2006, J NEUROSCI, V26, P1407, DOI 10.1523/JNEUROSCI.3463-05.2006
- Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22
- Smolka MN, 2005, J NEUROSCI, V25, P836, DOI 10.1523/JNEUROSCI.1792-04.2005
- Sole B, 2012, ACTA PSYCHIAT SCAND, V125, P309, DOI 10.1111/j.1600-0447.2011.01759.x
- SPRAGUE RL, 1977, SCIENCE, V198, P1274, DOI 10.1126/science.337493
- Summers M, 2006, PSYCHOL MED, V36, P1799, DOI 10.1017/S0033291706008804
- Takahashi H, 2010, J NEUROSCI, V30, P3043, DOI 10.1523/JNEUROSCI.5689-09.2010
- Tessitore A, 2002, J NEUROSCI, V22, P9099
- Venn HR, 2004, BIPOLAR DISORD, V6, P286, DOI 10.1111/j.1399-5618.2004.00121.x
- Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19
- Winterer G, 2006, BIOL PSYCHIAT, V60, P578, DOI 10.1016/j.biopsych.2006.03.023
- YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
- [Anonymous], 2000, DIAGNOSTIC STAT MANU